IntelGenx Technologies Corp. (OTCMKTS:IGXT) have announced a licensing, development, and supply agreement with Chemo Group, allowing Chemo the license to commercialize two generic products for the USA market and another product for the rest of the globe.
SAINT-LAURENT, QUEBEC–(Marketwired – Sep 12, 2016) – IntelGenx Corp., (TSX VENTURE:IGX)(IGXT), today announced that they have entered into a licensing, development and supply agreement with Chemo Group (“Chemo”) granting Chemo the exclusive license to commercialize two generic products for the USA market and one product on a worldwide basis.
The Chemo Group is a privately held global pharmaceutical company with over 5,000 employees and operations in over 40 countries and revenues over $1.2 billion annually.
Under the terms of the agreement, Chemo has obtained certain exclusive rights to market and sell IntelGenx’ products in exchange for upfront and milestone payments, together with a share of the profits of commercialization. Chemo also has a right of first refusal to obtain the exclusive commercialisation rights for two of the products to include any country outside the USA.
“We are pleased to have established a partnership with a significant global pharmaceutical company,” commented Dr. Horst Zerbe, President and CEO of IntelGenx. “This is the first step into a long term strategic alliance. We see the completion of this deal as further validation of our oral delivery platforms and our ability to attract high quality partnerships. This partnership is the beginning of what we believe will lead to further product agreements in expanding our global reach of our innovative product pipeline.”
About Chemo Group:
CHEMO operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health.
While the main offices are located in Spain, Switzerland and Argentina, CHEMO is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers` needs in all major pharmaceutical markets.
CHEMO`s activity is organized in three synergistic business areas: Industrial, Branded and Biotech, with over 5,000 professionals in more than 40 countries, 20 state-of-the-art facilities, 9 specialized R&D centers, 12 commercial offices and more than 50 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world.
IntelGenx is a leading oral drug delivery company focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX.
IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.
The mathematical calculation that represents the degree of change over time is known as “percentage change”. In finance, it serves many purposes, and is often used to represent the price change of a commodity.
Percentage change can be applied to any quantity that is measured over time any given time period. Say you are tracking the price of a stock. If the price increased, the formula [(New Price – Old Price)/Old Price] is applied and then take that number and multiply it by 100. If the price of a stock decreased, the formula [(Old Price – New Price)/Old Price] is applied then multiplied by 100.
The formula can be used to track the prices of both individual commodities and large market listings, and also used to compare the values of different currencies. Balance sheets with comparative financial statements often will include prices of specific stocks at different time periods alongside the percentage change over the same periods of time. Over the past three months, IntelGenx Technologies Corp. (OTCMKTS:IGXT) has seen 1138900 shares trade hands on average.
Are IntelGenx Technologies Corp. (OTCMKTS:IGXT) Shares Ready to Explode? Sign up to our Newsletter to be the First to Know
Sign up to get our Free Penny Stock Picks Before the Street!
IntelGenx Technologies Corp. (OTCMKTS:IGXT) shares closed the most recent session at 0.897 moving from the previous open or $-0.002. This is compared to the stock’s 52-week high of 1 and 52-week low of 0.37.
Companies are ranked according to their market caps, falling into large-cap, mid-cap and small-cap categories.
Large-cap companies have a market cap north of $10 billion. These large companies have usually been in business for a long time, and are major participants in well-established sectors. Investors in large-cap companies don’t necessarily bank large returns in short time periods, though are rewarded with a constant increase in share value over the long run.
Mid-cap companies have a market cap of $2 billion – $10 billion. Mid-cap companies are usually established companies operating in an industry that is expected to experience quick growth. Mid-cap companies are usually in the middle of expansion. They carry higher risk than large-cap companies due to the fact that they are not as established, though their growth potential remains an attraction to investors.
Small-cap companies have a market cap of $300 million – $2 billion. These smaller companies are usually newer or perhaps service a niche market or a new industry. Generally considered to be a higher risk than mid or large-cap in part because of their age, their size and the markets they serve. Small-cap companies usually have fewer resources and are more sensitive to the ebb-and-flow of markets. IntelGenx Technologies Corp. (OTCMKTS:IGXT)’s market cap currently sits at $72550000.
Sign Up to Receive Breaking Alerts on Stocks That Are Primed to Make a Run in the Bar Below.
Sign up to get our Free Penny Stock Picks Before the Street!
Disclaimer: The advice provided on this website is general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs. Where quoted, past performance is not indicative of future performance.